Inclusion Criteria

- Only patients who are currently enrolled in protocol 02-N-0121 Study of Immune
Dysregulation in Patients with Sporadic Inclusion Body Myositis (s-IBM) will be
considered for enrollment in protocol 04-N-0133.

INCLUSION CRITERIA:

Patients with confirmed diagnosis of s-IBM willing to undergo therapy with Alemtuzumab.

Willingness and legal ability to give and sign informed study consent.

Willingness to travel to the Clinical Center for planned studies and treatment as required
by protocol.

Men and women of reproductive potential must agree to use an acceptable method of birth
control during and for six months after completion of treatment.

Availability of tissue for testing. This will include muscle and peripheral blood
lymphocytes isolated through routine lymphocytapheresis or phlebotomy.

EXCLUSION CRITERIA:

Immunosuppressive drug therapy at the time of or 6 months prior to enrollment.
Specifically, candidates may not be taking Prednisone, cyclosporine, tacrolimus,
azathioprine, mycophenolate mofetil, anti-lymphocyte agents, cyclophosphamide
methotrexate, or other agents whose concomitant use may enhance the toxicity of
Alemtuzumab.

Any medical or personal difficulties that precludes serial follow-up visits.

Any active malignancy.

Significant coagulopathy or requirement for anticoagulation therapy that would
contraindicate protocol.

Platelet count less than 100,000/mm(3).

Hemoglobin less than 9.0 mg/dl.

Any known immunodeficiency syndrome included HIV infection.

Any history of cardiac insufficiency, major vascular disease, or unstable coronary artery
disease.

Any history of systemic or pulmonary edema.

Any history of previous treatment with monoclonal antibodies or sensitivity to the study
drug (Alemtuzumab), pre-medication regimen, or prophylactic agents.

History of chronic hypotension (SBP less than 100 mmHg).

Any medical condition that would likely increase the risk of side effects of the study
drug or confound the interpretation of the data including active infections.

Pregnancy and active nursing (breast feeding).

History of uncontrolled thyroid disease or a history of autoimmune thyroiditis.